These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 26010678)

  • 1. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.
    Tarantino MD; Collins PW; Hay CR; Shapiro AD; Gruppo RA; Berntorp E; Bray GL; Tonetta SA; Schroth PC; Retzios AD; Rogy SS; Sensel MG; Ewenstein BM;
    Haemophilia; 2004 Sep; 10(5):428-37. PubMed ID: 15357767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.
    Blanchette VS; Shapiro AD; Liesner RJ; Hernández Navarro F; Warrier I; Schroth PC; Spotts G; Ewenstein BM;
    J Thromb Haemost; 2008 Aug; 6(8):1319-26. PubMed ID: 18503631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice.
    Oldenburg J; Goudemand J; Valentino L; Richards M; Luu H; Kriukov A; Gajek H; Spotts G; Ewenstein B
    Haemophilia; 2010 Nov; 16(6):866-77. PubMed ID: 20579113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A.
    Auerswald G; Thompson AA; Recht M; Brown D; Liesner R; Guzmán-Becerra N; Dyck-Jones J; Ewenstein B; Abbuehl B
    Thromb Haemost; 2012 Jun; 107(6):1072-82. PubMed ID: 22476554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.
    Iorio A; Marcucci M; Cheng J; Oldenburg J; Schoenig-Diesing C; Matovinovic E; Romanov V; Thabane L
    Haemophilia; 2014 Nov; 20(6):777-83. PubMed ID: 25039809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A.
    Motwani J; Guillet B; Blatny J; Schilling FH; Wibaut B; Goldstine J; Nagy A; Doralt J; Engl W; Tangada S; Spotts G
    Haemophilia; 2020 May; 26(3):478-486. PubMed ID: 32338433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
    Den Uijl I; Mauser-Bunschoten EP; Roosendaal G; Schutgens R; Fischer K
    Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.
    Dhillon S
    Drugs; 2012 May; 72(7):987-1007. PubMed ID: 22564135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
    Bonanad S; Núñez R; Poveda JL; Kurnik K; Goldmann G; Andreozzi V; Vandewalle B; Santos S
    Adv Ther; 2021 Sep; 38(9):4872-4884. PubMed ID: 34368918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
    Négrier C; Shapiro A; Berntorp E; Pabinger I; Tarantino M; Retzios A; Schroth P; Ewenstein B
    Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
    Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
    Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study.
    Ewenstein BM; Gomperts ED; Pearson S; O'Banion ME
    Haemophilia; 2004 Sep; 10(5):491-8. PubMed ID: 15357776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
    Shah A; Solms A; Garmann D; Katterle Y; Avramova V; Simeonov S; Lissitchkov T
    Clin Pharmacokinet; 2017 Sep; 56(9):1045-1055. PubMed ID: 28005225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
    Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
    Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.
    Kitchen S; Beckmann H; Katterle Y; Bruns S; Tseneklidou-Stoeter D; Maas Enriquez M
    Haemophilia; 2016 May; 22(3):e192-9. PubMed ID: 27030173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A.
    Shapiro A; Gruppo R; Pabinger I; Collins PW; Hay CR; Schroth P; Casey K; Patrone L; Ehrlich H; Ewenstein BM
    Expert Opin Biol Ther; 2009 Mar; 9(3):273-83. PubMed ID: 19216617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK.
    Ewenstein BM; Collins P; Tarantino MD; Negrier C; Blanchette V; Shapiro AD; Baker D; Spotts G; Sensel M; Yi SE; Gomperts ED
    Semin Hematol; 2004 Jan; 41(1 Suppl 2):1-16; discussion 16-8. PubMed ID: 15071785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.
    Chen R; Gultyaev D; Lister J; Han R; Hu N; Malacan J; Solms A; Vashi P; O'Hara J; Hu S
    BMC Med Res Methodol; 2022 Aug; 22(1):215. PubMed ID: 35931967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.